Jove
Visualize
Contact Us

Related Experiment Videos

[Long-term survival in multiple myeloma]

A Sakalová1, M Mikulecký, L Dedík

  • 1Subkatedra hematológie a transfuziológie FN LFUK, Bratislava.

Vnitrni Lekarstvi
|February 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors influencing overall survival and GvHD development after allogeneic hematopoietic stem cell transplantation - single centre experience.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2024
Same author

Influence of different spectra of NOTCH3 variants on the clinical phenotype of CADASIL - experience from Slovakia.

Neurogenetics·2022
Same author

Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib.

Bratislavske lekarske listy·2021
Same author

The use of granulocyte colony stimulating factor after autologous hematopoietic stem cell transplantation.

Bratislavske lekarske listy·2019
Same author

Diagnostic Tools of Waldenströms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2017
Same author

Autologous hematopoietic stem cell transplantation for acute myeloid leukemia - single center experience.

Neoplasma·2017
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Intensive combined treatments for multiple myeloma significantly improve long-term survival, with over 15% of patients living beyond 10 years. Immunomodulation further enhances therapeutic effects and survival duration.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Medicine

Context:

  • Presents 23-year protocol study results for multiple myeloma survival.
  • Analyzes data from 535 diagnosed patients (1970-1990), with 475 regularly monitored and treated.
  • Includes 60 latent forms managed based on symptom progression.

Purpose:

  • To evaluate long-term survival outcomes in multiple myeloma patients.
  • To assess the efficacy of different treatment protocols, including monotherapy and combined therapies (COPP, VMCP, MOCCA).
  • To determine the impact of immunomodulation on treatment response and survival.

Summary:

  • Combined intensive treatments like VMCP and MOCCA demonstrated superior outcomes, with a median survival exceeding 90 months for stage II and III disease.

Related Experiment Videos

  • Objective response rates reached 85% with a low risk of complications (1.1%).
  • Immunomodulatory therapies (Interferon, proteolytic enzymes, thymus factor) positively influenced therapeutic effects and survival periods.

    • Impact:

    • Highlights the critical role of combined intensive treatment in improving multiple myeloma prognosis.
    • Demonstrates the feasibility and effectiveness of long-term management strategies for multiple myeloma.
    • Suggests immunomodulation as a valuable adjunct for enhancing survival in multiple myeloma patients.